UBS Group AG Sells 49,351 Shares of Privia Health Group, Inc. $PRVA

UBS Group AG trimmed its position in shares of Privia Health Group, Inc. (NASDAQ:PRVA) by 15.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 265,251 shares of the company’s stock after selling 49,351 shares during the period. UBS Group AG’s holdings in Privia Health Group were worth $6,289,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Canada Pension Plan Investment Board increased its holdings in Privia Health Group by 48.0% during the second quarter. Canada Pension Plan Investment Board now owns 3,700 shares of the company’s stock worth $85,000 after buying an additional 1,200 shares during the last quarter. GAMMA Investing LLC increased its holdings in Privia Health Group by 198.5% during the fourth quarter. GAMMA Investing LLC now owns 4,314 shares of the company’s stock worth $102,000 after buying an additional 2,869 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Privia Health Group during the second quarter worth $113,000. Covestor Ltd increased its holdings in Privia Health Group by 39.8% during the third quarter. Covestor Ltd now owns 5,824 shares of the company’s stock worth $145,000 after buying an additional 1,657 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in Privia Health Group during the first quarter worth $154,000. 94.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

PRVA has been the topic of a number of recent analyst reports. Evercore set a $26.00 target price on shares of Privia Health Group in a report on Wednesday, April 8th. Weiss Ratings downgraded shares of Privia Health Group from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday, May 8th. Barclays boosted their target price on shares of Privia Health Group from $23.00 to $25.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 25th. Canaccord Genuity Group lowered their target price on shares of Privia Health Group from $35.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, May 8th. Finally, Piper Sandler restated an “overweight” rating and set a $36.00 target price on shares of Privia Health Group in a report on Thursday, February 26th. Eleven investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $31.23.

Insiders Place Their Bets

In other Privia Health Group news, CEO Parth Mehrotra sold 105,439 shares of Privia Health Group stock in a transaction on Monday, May 11th. The shares were sold at an average price of $22.55, for a total transaction of $2,377,649.45. Following the completion of the transaction, the chief executive officer directly owned 450,004 shares of the company’s stock, valued at $10,147,590.20. The trade was a 18.98% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Matthew Shawn Morris sold 17,096 shares of the business’s stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $24.99, for a total transaction of $427,229.04. Following the completion of the sale, the director directly owned 68,188 shares of the company’s stock, valued at approximately $1,704,018.12. The trade was a 20.05% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 398,726 shares of company stock valued at $9,107,491. Company insiders own 5.70% of the company’s stock.

Privia Health Group Price Performance

PRVA stock opened at $23.29 on Wednesday. The company has a fifty day moving average price of $22.61 and a two-hundred day moving average price of $23.18. Privia Health Group, Inc. has a one year low of $18.77 and a one year high of $26.51. The stock has a market cap of $2.93 billion, a price-to-earnings ratio of 145.57, a price-to-earnings-growth ratio of 1.74 and a beta of 0.96.

Privia Health Group (NASDAQ:PRVA) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.19 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.11. Privia Health Group had a net margin of 0.97% and a return on equity of 2.81%. The firm had revenue of $603.85 million during the quarter, compared to analysts’ expectations of $560.99 million. During the same period in the previous year, the business posted $0.22 earnings per share. The company’s revenue for the quarter was up 25.8% compared to the same quarter last year. Research analysts anticipate that Privia Health Group, Inc. will post 0.35 EPS for the current fiscal year.

Privia Health Group Profile

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.